Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | RARB | P10826 | 2/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19440734 | 0.74 | PIM1 (0.32) | TNKSPARP1TNKS2PTGS1PTGS2 | |
| SCHEMBL25700442 | 0.71 | BACE1 (0.34) | TNKSPARP1TNKS2DHODHPTGS1 | |
| SCHEMBL21788088 | 0.70 | SMN1; SMN2 (0.41) | TNKSPARP1TNKS2DHODHPTGS1 | |
| SCHEMBL21758862 | 0.68 | PTGS1 (0.33) | TNKSPARP1TNKS2DHODHPTGS1 | |
| SCHEMBL24630602 | 0.68 | ALDH1A1 (0.41) | ESR1ESR2TNKSPARP1TNKS2 | |
| SCHEMBL27117088 | 0.68 | CYP1A2 (0.43) | TNKSPARP1TNKS2PTGS1PTGS2 | |
| SCHEMBL24061881 | 0.67 | AR (0.43) | DHODHPTGS2 | |
| SCHEMBL24183547 | 0.66 | NR3C1 (0.35) | — | |
| SCHEMBL15853166 | 0.65 | ESR1 (0.44) | ESR1ESR2RARBRARGHSD17B1 | |
| SCHEMBL26179235 | 0.65 | PTGS1 (0.42) | RARBRARGTNKS2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| US-10428047-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428047-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | ESR1 1945/4885ESR2 2029/4885RARB 3447/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | ESR1 1945/4885ESR2 2029/4885RARB 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.